Article
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
International journal of molecular sciences - 26 Feb 2022
Okada Masahiro, Shimizu Kanako, Fujii Shin-Ichiro
Abstract excerpt
The clinical benefits of immune checkpoint blockage (ICB) therapy have been widely reported. In patients with cancer, researchers have demonstrated the clinical potential of antitumor cytotoxic T cells that can be reinvigorated or enhanced by ICB. Compared to self-antigens, neoantigens derived from tumor somatic mutations are believed to be ideal immune targets in tumors. Candidate tumor neoantigens can be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
